SOUTH SAN FRANCISCO, CA--(Marketwire - November 03, 2008) - Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that data relating to a Phase IIa clinical trial for CK-1827452 are scheduled to be presented during a Special Program at the 2008 Scientific Sessions of the American Heart Association which is being held November 8-12, 2008 at the Ernest N. Morial Convention Center in New Orleans, La. These data represent an additional interim analysis of results from Cohorts 1 through 3 and four additional patients from Cohort 4 in an ongoing clinical trial evaluating CK-1827452 in stable heart failure patients. CK-1827452 is a novel cardiac myosin activator being developed for the potential treatment of patients with either acutely decompensated or chronic heart failure.
